Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899679 | 0.91 | OPRL1 (0.43) | NLRP3OPRL1KCNH2GRIN2B | |
| SCHEMBL4898569 | 0.90 | OPRL1 (0.36) | ADRA1AMCHR1NLRP3OPRL1 | |
| SCHEMBL4897645 | 0.89 | ADRA1A (0.37) | ADRA1AMCHR1AVPR1AOPRL1 | |
| SCHEMBL4935988 | 0.88 | OPRL1 (0.47) | ADRA1AMCHR1AVPR1AOPRL1 | |
| SCHEMBL4668777 | 0.83 | OPRL1 (0.40) | NLRP3OPRL1 | |
| Citric Acid SCHEMBL4936359 | 0.81 | OPRL1 (0.42) | ADRA1AMCHR1AVPR1AOPRL1 | |
| SCHEMBL4808544 | 0.80 | OPRL1 (0.43) | ADRA1AMCHR1OPRL1 | |
| SCHEMBL4939794 | 0.79 | OPRL1 (0.56) | ADRA1AMCHR1OPRL1 | |
| SCHEMBL4900212 | 0.79 | OPRL1 (0.36) | ADRA1AMCHR1AVPR1AOPRL1 | |
| SCHEMBL4932624 | 0.78 | OPRL1 (0.46) | ADRA1AMCHR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | OPRL1, OPRD1, OGFRL1 | ADRA1A 36/4885MCHR1 336/4885NLRP3 280/4885 |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | OPRL1, OGFRL1, OPRD1 | ADRA1A 43/4885MCHR1 288/4885NLRP3 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.